Aethlon Medical Appoints Raveendran ``Ravi'' Pottathil, Ph.D., to Scientific Advisory Board.

Business Editors/Health & Medical Writers

SAN DIEGO--(BW HealthWire)--Oct. 23, 2001

Aethlon Medical Inc. (OTCBB:AEMD) announced today that Raveendran (Ravi) Pottathil, Ph.D., a recognized authority in the field of HIV/AIDS diagnostics and therapeutics, has been appointed to its Scientific Advisory Board.

"Dr. Pottathil is one of the most talented and intelligent scientists I have ever had the pleasure to interact with," said Richard Tullis, Ph.D., chief scientific officer at Aethlon. "His broad interests and experience in viral diagnostics and therapy represent a significant and vital addition to Aethlon's core team."

Dr. Pottathil is the former Section Manager for Retroviruses (focus on HIV and HCV) and Tumor markers and PCR diagnostics at Hoffman La Roche from 1985 to 1992. Upon completing his tenure at Roche, Dr. Pottathil co-founded Specialty Biosystems Inc., a venture of Specialty Labs, one of the largest independent reference laboratories in California. Dr. Pottathil has also advised the World Health Organization's Sexually Transmitted Diseases and Global Vaccination Program.

Dr. Pottathil has worked with Dr. Robert Huebner of the NIH in immunology and virology at The Jackson Laboratory, and with Drs. David Lang and Wolfgang Joklik at Duke University on interferons, anti-tumor RNAs and antigenic suppression of tumorigenic retroviruses. Academic positions include: Assistant Professor at the University of Maryland School of Medicine; Associate Professor at the City of Hope Medical Center in Duarte, Calif. where he published extensively with Dr. Pedro Cuatrecasas (one of developers of affinity chromatography); and Adjunct Professor in Cellular and Molecular Biology at Down State Medical Center and Rutgers University.

As a virologist and molecular biologist, Dr. Pottathil has over 40 refereed publications to his credit and has been a Director of OncQuest Inc., GeneQuest Inc., Specialty Laboratories Asia in Singapore and Specialty Ranbaxy in India. Currently, Dr. Pottathil is the president of AccuDx Inc. a pharmaceutical diagnostics company he founded in 1996.

The addition of Dr. Pottathil represents Aethlon's increased focus to expand the membership of its Scientific Advisory Board to include recognized leaders from the infectious disease industry, specifically those with expertise in treating HIV/AIDS and Hepatitis C.

Aethlon Medical is a development stage company that is expanding the applications of a novel, global therapeutic approach for treating HIV/AIDS and other epidemic diseases. The company's platform technology, known as the Hemopurifier(TM), is designed to rapidly reduce the presence of viruses and other intoxicants in the blood. The near term business strategy is to develop new therapies and standards of care for infectious diseases in two major revenue sectors, HIV/AIDS and Hepatitis-C (HCV). Aethlon Medical's lead product candidates, AEMD-45 and AEMD-61, are positioned to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, decrease treatment resistance, and protect immune functions. Pre-clinical trials of AEMD-45 consistently document a 55 percent removal of HIV from whole human blood in three hours and an 85-100 percent removal of HIV during the equivalent of one overnight treatment. For more information on Aethlon Medical Inc., visit the company's Web site at www.AethlonMedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the Company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.